# US Psoriasis Treatment Market

> US Psoriasis Treatment Market Research Report: Size, Share, Trend Analysis By Treatment Type (Topical Treatments, Systemic Treatments, Phototherapy, Biologics), By Administration Route (Oral, Topical, Injectable, Intravenous), By Indication (Plaque Psoriasis, Guttate Psoriasis, Inverse Psoriasis, Pustular Psoriasis) and By End Users (Hospital, Dermatology Clinics, Homecare Settings) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.43%
- **2024:** $ 1,564.5 Million
- **2025:** $ 1,633.81 Million
- **2035:** $ 2,520 Million
- **Key Players:** AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Regeneron Pharmaceuticals (US), UCB (BE)

**Report ID:** MRFR/Pharma/14300-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** July 20, 2026

**URL:** https://www.marketresearchfuture.com/reports/us-psoriasis-treatment-market-15827

---

## Market Summary

## **US Psoriasis Treatment Market Overview**

As per MRFR analysis, the US Psoriasis Treatment Market Size was estimated at 1.62 (USD Billion) in 2023. The US Psoriasis Treatment Market Industry is expected to grow from 1.79 (USD Billion) in 2024 to 2.98 (USD Billion) by 2035. The US Psoriasis Treatment Market CAGR (growth rate) is expected to be around 4.743% during the forecast period (2025 - 2035).

### **Key US Psoriasis Treatment Market Trends Highlighted**

The US Psoriasis Treatment Market is witnessing significant trends driven by increased awareness of psoriasis and its treatments. Patients are becoming more informed about their options, encouraging demand for effective therapies. The growing prevalence of psoriasis in the US, attributed to factors such as obesity, smoking, and stress, propels the market forward. There is a notable shift towards biologic therapies, which provide targeted treatment methods for moderate to severe cases. These advancements in precision medicine are replacing traditional treatments, providing better efficacy and fewer side effects.

The rise of telemedicine has also changed how patients access care, allowing for easier consultations with dermatologists, which is particularly beneficial for those in remote areas or with mobility challenges.

Opportunities within this market include the development of personalized medicine, combining genetic research and new treatment modalities tailored to individual patient needs. Additionally, guided patient education and support programs have opened avenues for pharmaceutical companies to engage with patients, improve treatment adherence, and enhance quality of life. Recent trends indicate an increased focus on combination therapies, where multiple treatments are used together to achieve better management of the condition. Moreover, ongoing research and innovations continue to emerge, with new drug candidates entering clinical trials that may enhance treatment effectiveness and safety.

This is particularly pertinent in the US, where regulatory pathways are advancing rapidly, reflecting a supportive environment for the introduction of innovative therapies. Overall, the US Psoriasis Treatment Market is on an upward trajectory, driven by both patient demand and the continuous evolution of treatment options.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **US Psoriasis Treatment Market Drivers**

### **Rising Incidence of Psoriasis**

The increasing prevalence of psoriasis in the United States is a significant driver for the US Psoriasis Treatment Market Industry. According to data from the National Psoriasis Foundation, an estimated 7.5 million Americans are living with psoriasis, which is roughly 2-3% of the U.S. population. This increasing prevalence leads to greater demand for effective treatments, driving market growth. The population's awareness regarding skin diseases has also surged, resulting in a higher rate of diagnoses and subsequent treatment initiation.

This trend is further supported by the development of innovative therapies. For example, companies such as Amgen and Johnson & Johnson have launched biologics that are transforming treatment paradigms, making psoriasis management more effective and tailored, thus expanding the patient base seeking treatment.

### **Advancements in Treatment Options**

Innovative therapies and advancements in treatment options can significantly propel the US Psoriasis Treatment Market Industry. The introduction of biologics and targeted therapies has changed the approach to managing psoriasis, leading to higher efficiency and better patient outcomes. The American Academy of Dermatology notes that biologic treatments have undergone rapid development over the past few years, with multiple new products being approved by the U.S. Food and Drug Administration. This not only increases competition among pharmaceutical companies but also provides healthcare providers with an expanded toolkit to manage psoriasis.

As a result, the availability of diverse treatment options is expected to grow, appealing to a wider range of patients and contributing to market growth.

### **Increased Patient Awareness and Education**

Rising patient awareness regarding psoriasis and its treatments is increasingly driving the US Psoriasis Treatment Market Industry. Various awareness campaigns conducted by organizations such as the National Psoriasis Foundation and American Academy of Dermatology focus on educating the public about skin health and the importance of seeking treatment. As more individuals recognize the symptoms and impact of psoriasis on their quality of life, they are more likely to seek medical attention.

A survey indicates that awareness regarding psoriasis has improved by nearly 35% among the general population over the past five years, which is pivotal in aiding early diagnosis and facilitating appropriate treatment pathways.

### **Growing Investment in Healthcare Infrastructure**

The growth of investment in healthcare infrastructure is also a vital driver for the US Psoriasis Treatment Market Industry. According to the Centers for Medicare and Medicaid Services, the U.S. healthcare spending is projected to grow at an average rate of 5.4% per year, reaching a substantial part of the GDP. This surge provides healthcare providers with improved resources, technologies, and facilities to manage and treat psoriasis effectively. Improved access to dermatology specialists and treatment centers translates into more patients receiving timely care.

Furthermore, robust investment in Research and Development by companies like Pfizer and AbbVie enhances the overall medication pipeline, driving better treatment options and improved patient outcomes.

## **US Psoriasis Treatment Market Segment Insights**

### **Psoriasis Treatment Market Treatment Type Insights**

The Treatment Type segment within the US Psoriasis Treatment Market encompasses a diverse range of therapeutic options aimed at addressing this chronic skin condition that affects millions in the United States. Topical Treatments, which are often the first line of defense, play a crucial role in managing symptoms by applying medications directly to the skin, thereby providing targeted relief for localized areas. Systemic Treatments are employed for more severe cases, offering comprehensive management through medications that work throughout the body, appealing particularly to individuals with widespread psoriasis or those unresponsive to topical therapies.

Phototherapy utilizes specific wavelengths of light to treat psoriasis effectively; this option not only serves as a critical alternative for many patients but is also endorsed for its potential to minimize systemic exposure to pharmaceuticals.

The increasing popularity of Biologics represents a significant shift in the market as they specifically target immune responses involved in psoriasis development, showcasing advanced mechanisms of action that help improve the quality of life for those affected. Overall, each treatment type contributes uniquely to the dynamic landscape of the US Psoriasis Treatment Market, responding to the varying needs of patients while highlighting ongoing advancements in dermatological therapies. The increasing awareness regarding treatment options, accompanied by the ongoing Research and Development in this sector, drives market growth and encourages patients and healthcare providers alike to explore these effective solutions.

As the treatment modalities evolve, understanding the nuances of each type continues to be pivotal for stakeholders in optimizing approaches for managing psoriasis, ultimately aiming to enhance patient outcomes and quality of life.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Psoriasis Treatment Market Administration Route Insights**

The US [Psoriasis Treatment](../../../reports/psoriasis-treatment-market-2769) Market has seen significant developments in its Administration Route segment, reflecting various approaches to patient care. This segment highlights the diverse methods available for delivering treatments, including Oral, Topical, Injectable, and Intravenous routes. Topical treatments are prominently used due to their localized effect, providing relief with minimal systemic exposure, and are often preferred for mild to moderate cases. In contrast, Injectable therapies have gained traction, especially with the advent of biologics, which target specific pathways in the immune response associated with psoriasis, offering more effective outcomes for severe cases.

Intravenous administration, although less common, plays a vital role in providing rapid treatment for patients needing immediate relief. Oral therapies remain popular as they offer convenience and ease of use, appealing to a broad patient base. These varied administration routes not only cater to the diverse needs of patients but also adapt to evolving treatment paradigms in the US, thereby enhancing overall treatment adherence and effectiveness. The continuous introduction of novel therapies through these routes reflects ongoing Research and Development efforts aimed at improving patient outcomes in the management of psoriasis.

### **Psoriasis Treatment Market Indication Insights**

The US Psoriasis Treatment Market is characterized by various indications that highlight the diverse needs of patients suffering from this chronic skin condition. Among these indications, Plaque Psoriasis is particularly significant, as it affects the majority of psoriasis patients with well-defined, raised lesions. Guttate Psoriasis, often triggered by infections, presents a different challenge and is more common in children and young adults, emphasizing the need for age-appropriate treatments.

Inverse Psoriasis, which occurs in skin folds, can be challenging to manage due to its sensitivity and the discomfort it causes, while Pustular Psoriasis, although less common, requires effective intervention due to the potential severity of symptoms.

The distinctions among these indications lead to differing treatment approaches, thereby influencing the US Psoriasis Treatment Market segmentation. This variability within the indication segment is crucial as it informs healthcare providers and pharmaceutical companies about the specific requirements for effective management of psoriasis, thereby driving innovation and developments in treatment therapies tailored for each type.

### **Psoriasis Treatment Market End User Insights**

The End User segment of the US Psoriasis Treatment Market includes hospitals, dermatology clinics, and homecare settings, each playing a vital role in the management and treatment of psoriasis. Hospitals signify a substantial portion of the market, equipped with advanced facilities and specialists that offer comprehensive care for severe cases. Dermatology clinics focus particularly on skin-related conditions, providing targeted therapies and support, making them a preferred choice for patients seeking specialized attention. Homecare settings are becoming increasingly significant, enabling patients to manage their treatment in the comfort of their homes, which is important for those seeking convenience and personalized care.

The rise in the prevalence of psoriasis in the United States, along with increasing awareness about treatment options and the growing demand for tailored therapies, fuel the growth of these segments. Moreover, the integration of telehealth services is enhancing accessibility in dermatology clinics and homecare settings, making it easier for patients to receive ongoing medical advice. This diverse segmentation highlights the various pathways of care available to individuals suffering from psoriasis, illustrating the evolving landscape of treatment options in the US Psoriasis Treatment Market.

## **US Psoriasis Treatment Market Key Players and Competitive Insights**

The US Psoriasis Treatment Market is characterized by intense competition, driven by a rising prevalence of psoriasis among the population, awareness regarding treatment options, and advancements in therapeutic technologies. This market includes a diverse range of treatment modalities, including biologics, systemic therapies, and topical treatments, which cater to different severity levels and patient preferences. As research and development continue to innovate in this space, various pharmaceutical companies are striving to secure their positions through strategic collaborations, product launches, and expanding their portfolios.

The landscape is also influenced by regulatory frameworks, pricing strategies, and the burgeoning demand for tailored therapies to enhance patient outcomes. All these factors play a vital role in shaping the competitive dynamics of the market.

Celgene holds a notable position within the US Psoriasis Treatment Market, particularly recognized for its commitment to developing innovative therapies that address the unmet needs of psoriasis patients. The company's strength lies in its robust pipeline, which includes several biologics that demonstrate significant efficacy in treating moderate to severe psoriasis. This focus on research and development has positioned Celgene as a formidable player in the market, allowing it to leverage its existing product portfolio and expand its therapeutic options.

Furthermore, Celgene's strong sales and marketing strategies enhance its visibility among healthcare professionals, while its commitment to patient support programs underscores its dedication to improving treatment adherence and patient satisfaction in the US region.

Novartis is another key competitor in the US Psoriasis Treatment Market, with a strong emphasis on developing integrated treatment solutions that cater to diverse patient needs. The company is known for its leading products that have become go-to options for the management of psoriasis. Novartis has strategically expanded its market presence through a series of mergers and acquisitions, which have significantly bolstered its portfolio of psoriasis therapies. Their investments in innovative therapies, including biologics and targeted therapies, have established Novartis as a market leader.

Additionally, Novartis focuses on patient-centric approaches, ensuring that its offerings not only meet clinical efficacy but also improve overall quality of life for individuals suffering from psoriasis. The company's robust distribution network further amplifies its reach within the US market, contributing to its competitive stance in the rapidly evolving landscape of psoriasis treatments.

### **Key Companies in the US Psoriasis Treatment Market Include**

## **US Psoriasis Treatment Market Industry Developments**

In recent developments within the US Psoriasis Treatment Market, significant advancements have been made by major players such as Novartis and AbbVie, launching upgraded formulations that have shown improved efficacy in clinical trials. For example, AbbVie's drug Humira continues to dominate the market while new entrants are closely following. Moreover, in September 2023, Regeneron Pharmaceuticals announced a strategic partnership with Sanofi to enhance the delivery of their eczema and psoriasis therapies, showcasing collaboration among leading firms.

Current affairs reflect a growing consumer demand for personalized medicine, prompting companies like Eli Lilly and Amgen to invest heavily in Research and Development for biologic treatments.

In merger and acquisition news, Bristol Myers Squibb completed its acquisition of Myokardia in October 2023, aimed at expanding its cardiovascular portfolio, which may indirectly impact its psoriasis product strategy. Market valuation has steadily grown, with the US Psoriasis Treatment Market estimated to reach $12 billion by 2025, primarily driven by innovative drugs and increasing prevalence rates as reported by the Centers for Disease Control and Prevention (CDC). Such growth highlights an evolving landscape with promising opportunities for both established companies and newcomers entering the psoriasis treatment sector.

## **US Psoriasis Treatment Market Segmentation Insights**

### **Psoriasis Treatment Market Treatment Type Outlook**

### **Psoriasis Treatment Market Administration Route Outlook**

### **Psoriasis Treatment Market Indication Outlook**

### **Psoriasis Treatment Market End User Outlook**

## Market Drivers

### Rising Healthcare Expenditure

The increasing healthcare expenditure in the US is a significant driver for the psoriasis treatment market. As healthcare spending continues to rise, patients are more likely to seek treatment for chronic conditions such as psoriasis. In 2025, healthcare expenditure is projected to reach approximately $4 trillion, indicating a growing willingness to invest in health and wellness. This trend is likely to result in higher demand for psoriasis treatments, as patients prioritize managing their conditions effectively. Additionally, insurance coverage for advanced therapies is improving, making treatments more accessible to a broader population. Consequently, the psoriasis treatment market is expected to expand as more individuals seek effective management options for their condition.

### Growing Prevalence of Psoriasis

The increasing prevalence of psoriasis in the US is a primary driver for the psoriasis treatment market. Recent estimates suggest that approximately 7.5 million individuals in the US are affected by this chronic skin condition. This rising number of patients necessitates a corresponding increase in treatment options, thereby expanding the market. The psoriasis treatment market is likely to experience growth as healthcare providers seek to address the needs of this expanding patient population. Furthermore, the demand for effective therapies is heightened by the chronic nature of the disease, which often requires long-term management. As awareness of psoriasis continues to grow, the market may see a shift towards more innovative and personalized treatment solutions.

### Advancements in Treatment Modalities

Innovations in treatment modalities are significantly influencing the psoriasis treatment market. The introduction of novel therapies, including biologics and targeted therapies, has transformed the landscape of psoriasis management. For instance, biologics have shown efficacy rates of up to 90% in some patients, which is a substantial improvement over traditional treatments. This advancement not only enhances patient outcomes but also drives market growth as healthcare providers increasingly adopt these new therapies. Additionally, the development of combination therapies that integrate different treatment approaches may further expand the options available to patients. As the market evolves, the focus on personalized medicine is likely to become more pronounced, catering to the unique needs of individuals suffering from psoriasis.

### Regulatory Support for New Treatments

Regulatory support for the approval of new treatments is a crucial driver for the psoriasis treatment market. The US Food and Drug Administration (FDA) has streamlined the approval process for innovative therapies, which encourages pharmaceutical companies to invest in the development of new psoriasis treatments. This regulatory environment is likely to facilitate the introduction of novel therapies that can address unmet medical needs in the psoriasis population. As new treatments receive expedited approval, the market may witness a surge in available options for patients. Furthermore, the FDA's commitment to patient-centered approaches may lead to the development of therapies that are not only effective but also improve the quality of life for individuals living with psoriasis.

### Increased Investment in Dermatology Research

The psoriasis treatment market is benefiting from heightened investment in dermatology research. Pharmaceutical companies and research institutions are allocating substantial resources to develop new therapies and improve existing ones. In 2025, it is estimated that the dermatology sector will see an investment increase of approximately 15%, reflecting the growing recognition of psoriasis as a significant public health issue. This influx of funding is likely to accelerate the pace of innovation, leading to the introduction of more effective treatment options. Moreover, collaborations between academia and industry are fostering a conducive environment for breakthroughs in psoriasis research. As a result, the market is poised for expansion, driven by the continuous quest for improved therapeutic solutions.

## Future Outlook

The [Psoriasis Treatment Market](https://www.marketresearchfuture.com/reports/psoriasis-treatment-market-2769) is projected to grow at a 4.43% CAGR from 2025 to 2035, driven by advancements in biologics, increased awareness, and rising healthcare expenditure.

**New opportunities:**

- Development of personalized biologic therapies for targeted patient demographics.
- Expansion of telehealth services for remote patient monitoring and consultations.
- Investment in digital health platforms for enhanced patient engagement and adherence.

By 2035, The psoriasis treatment market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Type: Biologics (Largest) vs. Topical Treatments (Fastest-Growing)

Within the US psoriasis treatment market, the segment breakdown by type shows that biologics continue to dominate with the largest market share. This is attributable to their effectiveness and the increasing prevalence of psoriasis cases. Topical treatments, while historically well-established, are being outpaced by innovations in systemic and [biologic](../../../reports/orthobiologics-market-7826) therapies, yet they still hold a significant portion of the market due to their accessibility and ease of use. Over recent years, growth trends in the US psoriasis treatment market have shifted towards biologics as patients increasingly opt for more targeted therapies. The rise in awareness about skin conditions and advancements in treatment options are driving demand for both systemic treatments and biologics. Additionally, the convenience and rapid results provided by these therapies are influencing patient choices and treatment plans, ensuring a competitive landscape for topical treatments as well.

Biologics (Dominant) vs. Topical Treatments (Emerging)

Biologics represent the dominant force in the psoriasis treatment market, offering advanced solutions that target specific immune pathways responsible for psoriasis flare-ups. Their clinical efficacy and tailored approaches address severe forms of the condition, making them a preferred choice among healthcare professionals and patients alike. In contrast, topical treatments, while emerging, remain an essential option for mild to moderate psoriasis due to their lower cost and ease of application. Patients often start with topical agents before progressing to biologics for more severe cases. Both segments highlight the diverse options available for treating psoriasis, catering to varying patient needs and conditions.

### By Administration Route: Oral (Largest) vs. Injectable (Fastest-Growing)

The market distribution among the administration routes for psoriasis treatments reveals that the oral segment holds the largest share, driven by its ease of use and patient preference. Topical treatments also maintain a significant presence, frequently utilized for localized therapy. Meanwhile, injectable options are gaining traction, showcasing a growing response among patients seeking effective management of their condition. Growth trends highlight injectable treatments as the fastest-growing segment, attributed to advancements in biologics and targeted therapies. As more patients look for effective and rapid relief from psoriasis symptoms, innovative drug formulations administered through injections are appealing. Additionally, increasing awareness and better diagnosis rates contribute to the rising adoption of various treatment routes, further driving market expansion.

Oral (Dominant) vs. Injectable (Emerging)

The oral administration route is dominating the treatment landscape due to its convenience and compliance among patients. Oral medications are often preferred for their practicality, allowing patients to manage their psoriasis without the need for injections. In contrast, injectable treatments are emerging rapidly, offering biologics that target specific pathways in the disease's progression. As healthcare providers shift focus towards personalized medicine, injectables are anticipated to enhance efficacy and patient satisfaction. Both segments cater to distinct patient needs, with oral treatments leading in established markets while injectables pave the way for future growth and innovation in psoriasis management.

### By Indication: Plaque Psoriasis (Largest) vs. Guttate Psoriasis (Fastest-Growing)

Among the different indications in the US psoriasis treatment market, plaque psoriasis commands the largest market share, accounting for a substantial majority of the total. This segment has long been recognized for its chronic nature and significant burden on patients, contributing to its dominance. On the other hand, guttate psoriasis has emerged as the fastest-growing segment, appealing increasingly to consumers due to its more acute presentation and varied treatment options. Growth trends indicate a rise in both awareness and treatment availability for different types of psoriasis, with plaque psoriasis consistently holding strong. However, the rapid increase in cases of guttate psoriasis, particularly among younger demographics, drives its growth. Factors such as innovation in treatment options and increasing investment in awareness campaigns are acting as catalysts for this expansion in the US psoriasis treatment market.

Plaque Psoriasis (Dominant) vs. Guttate Psoriasis (Emerging)

Plaque psoriasis, the dominant segment, is characterized by its chronic plaques that can significantly impact quality of life. Patients often require long-term care, leading to persistent demand for treatments such as topical therapies, phototherapy, and systemic options. The established nature of this indication ensures a steady market presence. Conversely, guttate psoriasis is labeled as an emerging segment, primarily affecting younger individuals and often triggered by infections. Its presentation as small, drop-like lesions allows for varied management approaches and a growing consumer base. As awareness and treatment accessibility improve, guttate psoriasis is poised for significant growth, appealing to a demographic seeking effective and immediate interventions.

### By End User: Hospital (Largest) vs. Dermatology Clinics (Fastest-Growing)

The US psoriasis treatment market showcases a diverse distribution among various end users, with hospitals holding the largest share due to their capacity to provide comprehensive care and advanced treatment options. Dermatology clinics also represent a significant segment, appealing to patients seeking specialized care tailored to their specific needs, which positions them as a robust competitor in this landscape. Growth trends indicate that dermatology clinics are the fastest-growing segment as patients increasingly prefer targeted treatments and personalized services. This shift is driven by the rising prevalence of psoriasis and the growing demand for specialized dermatological care. Additionally, innovations in treatment modalities and increased awareness among healthcare providers further bolster the stature of these clinics, projecting them as pivotal players in the future dynamics of the market.

Hospital (Dominant) vs. Dermatology Clinics (Emerging)

Hospitals remain the dominant end user in the US psoriasis treatment market, leveraging their extensive resources and multidisciplinary teams to manage complex cases effectively. They have established protocols to facilitate patient care, resulting in higher patient retention rates. In contrast, dermatology clinics are emerging as key players, providing focused and specialized treatment solutions that cater directly to psoriasis patients. The personalized approach and shorter wait times enhance patient satisfaction, making these clinics an attractive option. Additionally, the trend towards outpatient treatment options is favorable for dermatology clinics, potentially increasing their market share and positioning them for future growth as more patients seek convenient and accessible care.

## Competitive Benchmarking

The psoriasis treatment market is characterized by a dynamic competitive landscape, driven by a combination of innovation, strategic partnerships, and a focus on patient-centric solutions. Major players such as AbbVie (US), Amgen (US), and Bristol-Myers Squibb (US) are actively shaping the market through their robust portfolios and commitment to research and development. AbbVie (US) continues to leverage its leading position with the successful launch of new formulations, while Amgen (US) emphasizes its focus on biologics and personalized medicine. Bristol-Myers Squibb (US) is strategically positioned through its recent acquisitions, enhancing its capabilities in immunology and expanding its treatment options for psoriasis.
Key business tactics within the market include localized manufacturing and supply chain optimization, which are essential for meeting the diverse needs of patients across different regions. The competitive structure appears moderately fragmented, with several key players exerting influence over market dynamics. This fragmentation allows for a variety of treatment options, fostering innovation and competition among companies. The collective influence of these major players is significant, as they drive advancements in treatment efficacy and patient outcomes.
In October 2025, AbbVie (US) announced a strategic partnership with a leading telehealth provider to enhance patient access to its psoriasis treatments. This collaboration aims to integrate digital health solutions into the treatment pathway, potentially improving patient adherence and outcomes. The strategic importance of this move lies in AbbVie's recognition of the growing role of telehealth in chronic disease management, positioning itself as a leader in patient engagement.
In September 2025, Amgen (US) launched a new clinical trial for its innovative psoriasis therapy, which utilizes a novel mechanism of action. This trial aims to evaluate the long-term efficacy and safety of the treatment in diverse patient populations. The significance of this initiative is underscored by Amgen's commitment to advancing personalized medicine, which may lead to improved treatment options tailored to individual patient needs.
In August 2025, Bristol-Myers Squibb (US) completed the acquisition of a biotechnology firm specializing in next-generation biologics for autoimmune diseases. This acquisition is expected to bolster Bristol-Myers Squibb's pipeline and enhance its competitive edge in the psoriasis treatment market. The strategic importance of this move reflects a broader trend of consolidation within the industry, as companies seek to expand their therapeutic offerings and accelerate innovation.
As of November 2025, current competitive trends in the psoriasis treatment market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their capabilities and market reach. Looking ahead, competitive differentiation is likely to evolve, shifting from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately lead to improved patient outcomes and a more sustainable market environment.

## Recent News & Developments

In recent developments within the US Psoriasis Treatment Market, significant advancements have been made by major players such as Novartis and AbbVie, launching upgraded formulations that have shown improved efficacy in clinical trials. For example, AbbVie's drug Humira continues to dominate the market while new entrants are closely following. Moreover, in September 2023, Regeneron Pharmaceuticals announced a strategic partnership with Sanofi to enhance the delivery of their eczema and psoriasis therapies, showcasing collaboration among leading firms.

Current affairs reflect a growing consumer demand for personalized medicine, prompting companies like Eli Lilly and Amgen to invest heavily in Research and Development for biologic treatments.

In merger and acquisition news, Bristol Myers Squibb completed its acquisition of Myokardia in October 2023, aimed at expanding its cardiovascular portfolio, which may indirectly impact its psoriasis product strategy. Market valuation has steadily grown, with the US Psoriasis Treatment Market estimated to reach $12 billion by 2025, primarily driven by innovative drugs and increasing prevalence rates as reported by the Centers for Disease Control and Prevention (CDC). Such growth highlights an evolving landscape with promising opportunities for both established companies and newcomers entering the psoriasis treatment sector.

## Report Scope

| MARKET SIZE 2024 | 1564.5(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 1633.81(USD Million) |
| MARKET SIZE 2035 | 2520.0(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.43% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | AbbVie (US), Amgen (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Novartis (CH), Pfizer (US), Regeneron Pharmaceuticals (US), UCB (BE) |
| Segments Covered | Type, Administration Route, Indication, End User |
| Key Market Opportunities | Emergence of biologics and personalized therapies enhances treatment options in the psoriasis treatment market. |
| Key Market Dynamics | Rising demand for biologics drives innovation and competition in the psoriasis treatment market. |
| Countries Covered | US |

## Frequently Asked Questions

**Q: What was the overall market valuation of the US psoriasis treatment market in 2024?**
A: The overall market valuation was 1564.5 USD Million in 2024.

**Q: What is the projected market valuation for the US psoriasis treatment market by 2035?**
A: The projected valuation for 2035 is 2520.0 USD Million.

**Q: What is the expected CAGR for the US psoriasis treatment market during the forecast period 2025 - 2035?**
A: The expected CAGR during the forecast period 2025 - 2035 is 4.43%.

**Q: Which companies are considered key players in the US psoriasis treatment market?**
A: Key players include AbbVie, Amgen, Bristol-Myers Squibb, Johnson & Johnson, Novartis, Pfizer, Regeneron Pharmaceuticals, and UCB.

**Q: What were the valuations for biologics in the US psoriasis treatment market in 2024?**
A: The valuation for biologics was 614.5 USD Million in 2024, projected to reach 1000.0 USD Million by 2035.

**Q: How do topical treatments compare to systemic treatments in terms of market valuation?**
A: Topical treatments were valued at 300.0 USD Million in 2024, while systemic treatments were valued at 450.0 USD Million.

**Q: What is the market valuation for plaque psoriasis treatments in 2024?**
A: The market valuation for plaque psoriasis treatments was 800.0 USD Million in 2024, with projections reaching 1300.0 USD Million by 2035.

**Q: What segment had the highest valuation in the US psoriasis treatment market in 2024?**
A: Biologics had the highest valuation at 614.5 USD Million in 2024.

**Q: What is the projected valuation for injectable treatments by 2035?**
A: The projected valuation for injectable treatments is expected to reach 800.0 USD Million by 2035.

**Q: Which end user segment had the highest valuation in 2024?**
A: The hospital segment had the highest valuation at 600.0 USD Million in 2024.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-psoriasis-treatment-market-15827*